OakChart

Braveheart Bio Inc

BRVEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

20.90+1.28 (6.52%)
2026-11-12 06:24 CET
Market cap
1,881.82 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-26.50 USD m
Free cash flow, TTM
-24.37 USD m
EPS diluted, TTM
-0.32
P/E
-
Compare

Price

BRVE against its 20 and 50-day averages
2050beatmiss
20.0025.0030.001.6M3.3MVolumeAug 26Sep 26Oct 26Nov 26BRVEclose 20.9020-day 20.4250-day 22.3420.9052w high52w low

34.7% under the 52-week high of 32.00 on 7 Aug 2026. 52-week low 16.70 on 5 Nov 2026. Last 15 sessions, 33.1% high to low

Volume 1.08× normal · the line is the 50-bar volume average

Profile

BRVE
52-week range, 27% of the way up
16.7032.00

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

IPOAug 06, 2026
ATR, 14d1.71
Rel volume1.08
Short float24.41%
Insider own76.55%
Inst own9.09%

Snapshot

6 groups

Valuation

Index-
Market Cap1.88B
Enterprise Value1.53B
Income-
Sales-
Book/sh6.06
Cash/sh3.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOAug 06, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.45
P/C5.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio21.57
Current Ratio21.57
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.45
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-7585.71%
Sales Q/Q-
EarningsNov 10 AMC
EPS/Sales Surpr.-16.44% -

Ownership

Insider Own76.55%
Insider Trans14.70%
Inst Own9.09%
Inst Trans20.17%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.36%
SMA50-6.43%
SMA200-11.89%
Trades-

Technical

Shs Outstand82.07M
Shs Float21.11M
Short Float24.41%
Short Ratio11.39
Short Interest5.15M
52W High32.00 -34.69%
52W Low16.70 25.15%
Volatility11.14% 7.75%
ATR (14)1.71
RSI (14)50.41
Beta-
Rel Volume1.08
Avg Volume452.30K
Volume488,974

Performance

Perf Week3.95%
Perf Month8.12%
Perf Quarter-19.52%
Perf Half Y-
Perf YTD-30.79%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price45.50
Prev Close19.62
Price20.90
Change %6.52%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Aug 31, 2026InitiatedTTD CowenBuy
Aug 31, 2026InitiatedSStifelBuy$45+115.3%
Aug 31, 2026InitiatedJJefferiesBuy$48+129.7%
Aug 31, 2026InitiatedGGoldmanBuy$48+129.7%
Aug 31, 2026InitiatedCCantor FitzgeraldOverweight$40+91.4%

Peers

Mkt cap
TickerCompanyMkt cap
CYTKCytokinetics Inc8.15B
EWTXEdgewise Therapeutics Inc5.21B
MLYSMineralys Therapeutics Inc1.43B
NAMSNewAmsterdam Pharma Company NV2.48B
TNYATenaya Therapeutics Inc84.61M
BMYBristol-Myers Squibb Co128.59B
BBIOBridgeBio Pharma Inc15.49B
LXEOLexeo Therapeutics Inc252.01M
VERAVera Therapeutics Inc2.20B
TRVITrevi Therapeutics Inc2.11B

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
AH Bio Fund IV, L.P.10% OwnerAug 07 '26Buy18.001,100,00019,800,00010,232,420Aug 11 05:53 PM
Chimovits ErezDirectorAug 07 '26Buy18.001,940,00034,920,00011,901,826Aug 11 05:31 PM
ORBIMED ADVISORS LLCDirectorAug 07 '26Buy18.001,940,00034,920,00011,901,826Aug 11 05:27 PM
Forbion Growth Opportunities F10% OwnerAug 07 '26Buy18.001,920,00034,560,00011,640,546Aug 07 05:25 PM
Forbion Growth Opportunities F10% OwnerAug 07 '26Buy18.001,680,00030,240,00010,185,478Aug 07 05:25 PM
Rickey James PaulChief Financial OfficerAug 07 '26Buy18.0027,777499,986520,927Aug 07 04:41 PM
Viehbacher ChristopherDirectorAug 07 '26Buy18.0083,3331,499,994609,519Aug 07 04:31 PM
Malek David IDirectorAug 07 '26Buy18.004,16674,988533,845Aug 07 04:31 PM
Anderson Michele A.Chief Development OfficerAug 07 '26Buy18.001,11119,998332,161Aug 07 04:30 PM
Murdoch TravisCEO and PresidentAug 07 '26Buy18.0083,3331,499,9942,940,670Aug 07 04:30 PM
Lubner David CharlesDirectorAug 07 '26Buy18.0055,555999,99055,555Aug 07 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FMEDFidelity Disruptive Medicine ETFAUM: 30.30M
TMEDT. Rowe Price Health Care ETFAUM: 38.55M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.510-0.438-0.3230.000.005
2026Q22026-09-08-2.5102.686-0.2070.000.005
2026Q12026-06-03-1.210--0.1590.00--
2026Q4---0.448--0.004
2027Q1---0.358--0.004
2027Q2---0.403--0.004
2027Q3---0.450--0.004
2027Q4---0.457--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-113000.000.000.00
2026Q4S2026-11-103000.000.000.00
2026Q4S2026-09-093000.000.000.00
2026Q4S2026-08-283000.000.000.00
2026Q4R2026-11-11110-0.34-0.34-0.34
2026Q4R2026-11-10101-0.44-0.44-0.44
2026Q4R2026-09-09101-0.44-0.44-0.44
2026Q4R2026-08-28200-0.40-0.40-0.40
2026Q4R2026-08-27100-0.40-0.40-0.40
2026Q4E2026-11-11422-0.45-0.53-0.34
2026Q4E2026-11-10431-0.44-0.47-0.42
2026Q4E2026-10-16431-0.44-0.47-0.42
2026Q4E2026-09-09421-0.45-0.48-0.42
2026Q4E2026-08-28500-0.43-0.48-0.40

Estimate history

EPS, annual-0.734
Period2025
EPS, quarterly-0.001-0.004-0.657-0.159-0.207-0.323
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual0
Period2025
Sales, quarterly000000
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual90.03982.069
Period2025MRQ
Shares, quarterly90.03990.03990.03990.03990.03982.069
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY
Total Revenue0.000.00
Cost of Goods Sold Incl. D&A0.000.00
Gross Profit-0.000.00
Selling, General and Administrative Excl. Other30.1565.45
Research and Development17.5462.93
Other Operating Expense0.000.00
Operating Income-30.15-65.45
Interest Expense0.000.00
Unusual Expense0.001.30
Net Income Before Taxes-26.50-66.05
Income Taxes0.000.00
Consolidated Net Income-26.50-66.05
Net Income From Continuing Operations-26.50-66.05
Net Income-26.50-66.05
EPS (Recurring)-0.32-0.72
EPS (Basic, Before Extraordinaries)-0.32-0.73
EPS (Diluted)-0.32-0.73
EBITDA-30.15-65.45
Non-Operating Income (Expense)3.650.70
Other After Tax Adjustments0.000.00
Stock Option Compensation Expense2.790.18
Shares Outstanding82.0790.04
Market Capitalization1,881.821,881.82

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.00
Gross Profit-0.00-0.00-0.000.000.000.00
Selling, General and Administrative Excl. Other30.1515.8814.8559.290.380.10
Research and Development17.5411.1210.9158.780.350.09
Other Operating Expense0.000.000.000.000.000.00
Operating Income-30.15-15.88-14.85-59.29-0.38-0.10
Interest Expense0.000.000.000.000.000.00
Unusual Expense0.000.000.200.000.000.00
Net Income Before Taxes-26.50-14.99-14.28-59.12-0.38-0.10
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-26.50-14.99-14.28-59.12-0.38-0.10
Net Income From Continuing Operations-26.50-14.99-14.28-59.12-0.38-0.10
Net Income-26.50-18.60-14.28-59.12-0.38-0.10
EPS (Recurring)-0.32-0.21-0.16-0.66-0.00-0.00
EPS (Basic, Before Extraordinaries)-0.32-0.21-0.16-0.66-0.00-0.00
EPS (Diluted)-0.32-0.21-0.16-0.66-0.00-0.00
EBITDA-30.15-15.88-14.85-59.29-0.38-0.10
Non-Operating Income (Expense)3.650.890.770.170.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense2.791.091.760.00-0.00
Shares Outstanding82.0790.0490.0490.0490.0490.04
Market Capitalization1,881.822,011.47----

Balance sheet, annual

Currency USD, millions
Metric2025FY
Cash & Short Term Investments89.16
Short Term Receivables0.00
Inventories0.00
Other Current Assets0.12
Total Current Assets89.28
Net Property, Plant & Equipment0.00
Total Investments and Advances0.00
Other Assets0.07
Total Assets89.35
Short Term Debt Incl. Current Port. of LT Debt0.00
Accounts Payable1.06
Other Current Liabilities4.18
Total Current Liabilities5.24
Long Term Debt0.00
Provision for Risks Charges0.00
Other Liabilities0.09
Total Liabilities5.33
Non-Equity Reserves0.00
Preferred Stock - Carrying Value149.89
Common Equity-65.87
Total Shareholders Equity84.02
Accumulated Minority Interest0.00
Total Equity84.02
Total Liabilities & Stockholders Equity89.35
Book Value Per Share-0.73
Tangible Book Value Per Share-0.73
Price to Book Ratio3.45
Return on Invested Capital-78.62
Quick Ratio17.03
Current Ratio17.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY
Net Income-26.50-66.05
Depreciation0.00-
Other Funds (Non Cash)8.4462.42
Funds from Operations-18.05-3.63
Extraordinary Item0.000.00
Changes in Working Capital-6.321.62
Cash from Operating Activities-24.37-2.01
Capital Expenditures0.000.00
Net Assets From Acquisitions0.000.00
Sale of Fixed Assets and Businesses0.000.00
Purchase or Sale of Investments-382.450.00
Purchase of Investments-382.450.00
Sale Or Maturity of Investments0.000.00
Other Uses0.00-33.57
Other Sources0.000.00
Cash from Investing Activities-382.45-33.57
Cash Dividends Paid0.000.00
Preferred Dividends (Cash Flow)-0.00
Change in Capital Stock405.28124.74
Repurchase of Common Pref Stock-0.010.00
Sale of Common Pref Stock405.29124.74
Proceedsfrom Stock Options405.29124.74
Issuance or Reduction of Debt, Net0.000.00
Change in Long Term Debt0.000.00
Issuance of Long Term Debt0.000.00
Reduction of Long Term Debt0.000.00
Net Financing Active Other Cash Flow0.000.00
Other Financing Activities Uses0.000.00
Cash from Financing Activities405.28124.74
Net Change in Cash-1.5489.16
Free Cash Flow-24.37-2.01
Deferred Taxes & Investment Tax Credit-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments349.27122.8380.58---
Short Term Receivables0.000.000.00---
Inventories0.000.000.00---
Other Current Assets10.300.610.50---
Total Current Assets359.57123.4481.07---
Net Property, Plant & Equipment0.530.630.74---
Total Investments and Advances154.250.000.00---
Other Assets0.102.880.07---
Total Assets514.45126.9681.88---
Short Term Debt Incl. Current Port. of LT Debt0.410.380.37---
Accounts Payable1.982.677.74---
Other Current Liabilities14.286.011.89---
Total Current Liabilities16.679.0610.00---
Long Term Debt0.100.200.29---
Provision for Risks Charges0.000.000.00---
Other Liabilities0.070.090.09---
Total Liabilities16.859.3410.38---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.00213.52149.88---
Common Equity497.60-95.91-78.39---
Total Shareholders Equity497.60117.6171.49---
Accumulated Minority Interest0.000.000.00---
Total Equity497.60117.6171.49---
Total Liabilities & Stockholders Equity514.45126.9681.88---
Book Value Per Share6.06-1.07-0.87---
Tangible Book Value Per Share6.06-1.07-0.87---
Full-Time Employees-4930---
Price to Book Ratio3.45-20.97----
Return on Invested Capital-5.32-12.72-19.89---
Quick Ratio21.5713.638.11---
Current Ratio21.5713.638.11---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-26.50-14.99-14.28-59.12-0.38-0.10
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)8.441.091.7658.770.350.09
Funds from Operations-18.05-13.90-12.52-0.35-0.03-0.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.32-3.057.33-0.390.030.01
Cash from Operating Activities-24.37-16.95-5.19-0.740.000.00
Capital Expenditures0.000.01-0.040.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-382.450.000.000.000.000.00
Purchase of Investments-382.450.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-3.00-32.730.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-382.450.01-3.04-32.730.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock405.2859.20-0.36101.000.000.00
Repurchase of Common Pref Stock-0.010.000.000.000.000.00
Sale of Common Pref Stock405.2959.20-0.36101.000.000.00
Proceedsfrom Stock Options405.2959.20-0.36101.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities405.2859.20-0.36101.000.000.00
Net Change in Cash-1.5442.26-8.5967.530.000.00
Free Cash Flow-24.37-16.94-5.22-0.740.000.00

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.41%5.2M21.1M480.86K
2026-10-1523.24%4.9M21.1M528.37K
2026-09-30187.68%4.1M2.2M558.72K
2026-09-15111.87%2.5M2.2M456.34K
2026-08-3118.86%1.4M7.4M525.77K
2026-08-1411.44%0.8M7.4M953.04K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-09SCHEDULE 13GSEC
2026-11-068-KCurrent report2026-11-06SEC
2026-11-05SCHEDULE 13GSEC
2026-09-10SCHEDULE 13D/ASEC
2026-09-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-18SCHEDULE 13DSEC
2026-08-143Initial statement of beneficial ownership of securities2026-08-07SEC
2026-08-14SCHEDULE 13DSEC
2026-08-14SCHEDULE 13GSEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-078-KCurrent report2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-06424B4SEC
2026-08-06CERTSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08159.03M1100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC8.42%
GEODE CAPITAL MANAGEMENT, LLC0.32%
UBS Group AG0.25%
Squarepoint Ops LLC0.04%
Leonard Rickey Investment Advisors P.L.L.C.0.04%
CITIGROUP INC0.00%
SBI Securities Co., Ltd.0.00%

Funds

Fund% owned
Fidelity Growth Company Fund1.02%
Strategic Advisers Fidelity U.S. Total Stock Fund0.79%
Select Health Care Portfolio0.70%
MFS New Discovery Fund0.45%
Select Biotechnology Portfolio0.34%
Fidelity Growth Company K6 Fund0.29%
Fidelity Series Growth Company Fund0.25%
BlackRock Health Sciences Opportunities Portfolio0.15%
Strategic Advisers U.S. Total Stock Fund0.11%
BlackRock Advantage Small Cap Core Fund0.03%

OakChart. BRVE. Cached 15 minutes.

Some panels did not load: news.